Develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 (GLP-2). Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 38.8× for every dollar of annual revenue.
Analysts' average target sits 7% above today's price.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 30% below its peak. The market has trimmed its expectations for the company.
Sales run at $27.3M a year. A small number, but proof the product has real buyers.
A loss of $93.7M against $27.3M in annual sales.
At the current pace of spending, the cash lasts about 2.4 years. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.